Acadian Asset Management
GNCA

Acadian Asset Management’s Genocea Biosciences, Inc. GNCA Stock Holding History

Acadian Asset Management’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-21,741
Closed -$25K – 1904
2021
Q4 		$25K Buy
+21,741
New +$32.4K ﹤0.01% 1584
2020
Q2 		– Sell
-10,878
Closed -$19K – 2415
2020
Q1 		$19K Buy
+10,878
New +$22K ﹤0.01% 1659
2016
Q3 		– Sell
-111
Closed -$4K – 1617
2016
Q2 		$4K Buy
+111
New +$4.07K ﹤0.01% 1330

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Acadian Asset Management's GNCA Position: Q1 2022 in Review

Acadian Asset Management sold out of Genocea Biosciences, Inc. (GNCA) in Q1 2022, closing a stake of 21,741 shares — an estimated $25K sold.

Acadian Asset Management first reported a position in GNCA in Q2 2016 and held it in 3 quarters. The position peaked at $25K in Q4 2021. 40 funds tracked by Wall St. Rank hold GNCA as of Q1 2022.

  • Acadian Asset Management reported no remaining Genocea Biosciences, Inc. position as of Q1 2022 after selling out during the quarter.
  • Acadian Asset Management sold 21,741 Genocea Biosciences, Inc. shares in Q1 2022, an estimated $25K.
  • Acadian Asset Management first reported a position in Genocea Biosciences, Inc. in Q2 2016 and held it in 3 quarters.
  • Acadian Asset Management's Genocea Biosciences, Inc. position peaked at $25K in Q4 2021.
  • 40 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q1 2022.

Based on Acadian Asset Management's 13F filing for Q1 2022, filed 12 May 2022.